Hints of added benefit of enzalutamide in prostate cancer

Longer overall survival in patients without visceral metastases / bone complications and pain progression delayedEnzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic drug docetaxel.
Pain / Anesthetics News From Medical News Today

Share:

Related Content